NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis $1.62 +0.04 (+2.47%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CalciMedica Stock (NASDAQ:CALC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CalciMedica alerts:Sign Up Key Stats Today's Range$1.60▼$1.6550-Day Range$1.43▼$2.0652-Week Range$1.42▼$5.97Volume21,507 shsAverage Volume42,028 shsMarket Capitalization$22.62 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California. Read More CalciMedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreCALC MarketRank™: CalciMedica scored higher than 62% of companies evaluated by MarketBeat, and ranked 345th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalciMedica has only been the subject of 1 research reports in the past 90 days.Read more about CalciMedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalciMedica has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CalciMedica's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.73% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 2.48%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.73% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 2.48%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News SentimentN/A News SentimentCalciMedica has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CalciMedica this week, compared to 1 article on an average week.Search Interest2 people have searched for CALC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,580.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CalciMedica's insider trading history. Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address CALC Stock News HeadlinesCalcimedica (CALC) director Roberts buys $6k in sharesJune 29, 2025 | investing.comCalciMedica, Inc. (CALC) stock price, news, quote & history - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 6 at 2:00 AM | Paradigm Press (Ad)CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory FailureJune 25, 2025 | prnewswire.comCalciMedica Insiders Added US$1.05m Of Stock To Their HoldingsJune 13, 2025 | finance.yahoo.comCalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology MeetingJune 12, 2025 | prnewswire.comcalcimedica appoints baker tilly as new accounting firm after mergerJune 8, 2025 | uk.investing.comCalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesMay 15, 2025 | finanznachrichten.deSee More Headlines CALC Stock Analysis - Frequently Asked Questions How have CALC shares performed this year? CalciMedica's stock was trading at $3.54 at the beginning of the year. Since then, CALC shares have decreased by 54.3% and is now trading at $1.6190. How were CalciMedica's earnings last quarter? CalciMedica Inc. (NASDAQ:CALC) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CalciMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM). Company Calendar Last Earnings5/14/2025Today7/06/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALC CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$20.00 Low Stock Price Target$16.00 Potential Upside/Downside+1,011.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.70 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.81% Return on Assets-100.43% Debt Debt-to-Equity Ratio0.79 Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book1.51Miscellaneous Outstanding Shares13,970,000Free Float8,167,000Market Cap$22.62 million OptionableNo Data Beta1.24 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CALC) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.